Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001073443 | SCV001238985 | likely pathogenic | Retinal dystrophy | 2019-02-15 | criteria provided, single submitter | clinical testing | |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV001280719 | SCV001468032 | likely pathogenic | not provided | 2020-08-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001280719 | SCV002114450 | pathogenic | not provided | 2022-09-08 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Phe70*) in the LRP5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LRP5 are known to be pathogenic (PMID: 11719191, 16252235, 25711638). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 865885). This premature translational stop signal has been observed in individual(s) with clinical features of osteoporosis-pseudoglioma syndrome (PMID: 16252235). Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. |
Fulgent Genetics, |
RCV005049762 | SCV005684285 | pathogenic | Bone mineral density quantitative trait locus 1; Exudative vitreoretinopathy 4; Worth disease; Autosomal dominant osteopetrosis 1; Osteoporosis with pseudoglioma; Polycystic liver disease 4 with or without kidney cysts | 2024-03-14 | criteria provided, single submitter | clinical testing |